Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts
Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts: Monotherapy Versus Combined Therapy
Zagazig University
162 participants
Apr 3, 2022
INTERVENTIONAL
Conditions
Summary
To follow up the efficacy and safety of Candida antigen, bivalent HPV vaccine in treatment of common warts either mono or combined intralesional therapy
Eligibility
Inclusion Criteria1
- patients with multiple, recalcitrant, or non-recalcitrant common warts of different sites, sizes, duration, and with or without distant lesions will be enrolled in the study
Exclusion Criteria1
- Pregnant female. Hypersensitivity to Candida antigen or bivalent HPV vaccine
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05291845